Brazil's Anvisa Approves Gazyva for Lupus Treatment

Brazil's health regulator Anvisa approved Roche's Gazyva (obinutuzumab) for adults with moderate-to-severe lupus, citing reduced flare-ups and corticosteroid use. This expands the drug's approved indications beyond oncology, marking a notable regulatory milestone. The decision is based on clinical trial data, but real-world efficacy and access in Brazil remain to be seen.